©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Psychiatry. Sep 19, 2024; 14(9): 1404-1410
Published online Sep 19, 2024. doi: 10.5498/wjp.v14.i9.1404
Published online Sep 19, 2024. doi: 10.5498/wjp.v14.i9.1404
Effectiveness of anti-psychiatric treatment on visual and haptic perceptual disorder for a patient with Alzheimer’s disease: A case report
Ting Xu, Xi Mei, Zheng Zhao, Yue-Hong Liu, Cheng-Ying Zheng, Department of Psychiatry, Affiliated Kangning Hospital of Ningbo University, Ningbo 315201, Zhejiang Province, China
Co-first authors: Ting Xu and Xi Mei.
Author contributions: Xu T, Zhao Z and Liu YH participated in patient management and follow-up and collected patient information; Mei X searched the literature for the case description and wrote the first draft of manuscript; Zheng CY revised the first draft and prepared the final manuscript; All authors are actively involved in all steps of the contribution.
Informed consent statement: Written informed consent was obtained from the patient and his legally authorized representative for the publication of this case report in accordance with the journal’s patient consent policy.
Conflict-of-interest statement: The authors declare that they have no conflict of interest.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Corresponding author: Cheng-Ying Zheng, BSc, Professor, Department of Psychiatry, Affiliated Kangning Hospital of Ningbo University, No. 1 Zhuangyu South Road, Zhenhai District, Ningbo 315201, Zhejiang Province, China. zhengchengying@126.com
Received: April 30, 2024
Revised: August 22, 2024
Accepted: August 30, 2024
Published online: September 19, 2024
Processing time: 134 Days and 0 Hours
Revised: August 22, 2024
Accepted: August 30, 2024
Published online: September 19, 2024
Processing time: 134 Days and 0 Hours
Core Tip
Core Tip: Topical and anti-allergic drugs did not provide improvement. After admission the patient was diagnosed with psychiatric behavioral symptoms of brain atrophy due to Alzheimer’s disease. The patient was administered risperidone (0.5 mg) and duloxetine (2 mg/day). One week later, the dose of risperidone was increased to 2 mg/day, and that of duloxetine was increased to 60 mg/day. After 2 weeks of treatment the patient no longer had the sensation of insects biting a crawling and his mood stabilized.